Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Q3 FY2021 Earnings Presentation
29 slides from Jubilant Pharmova's earnings presentation, Feb 5, 2021
Slide 1: Financial Results Quarter Ended December 31, 2020
Financial Results Quarter Ended December 31, 2020
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Conference Call Details
Conference Call Details Date : February 05, 2021 Time : 05:00 pm IST Replay: February 05 to February 12, 2021 Dial-in: +91 22 7194 5757/ +91 22 66635757 Playback ID: 82354# 22
Slide 4: Chairmen’s Message
Chairmen’s Message JUBILANT Q3'FY21 PERFORMANCE Q3’FY21 Revenue at Rs 2,664 Crore vs. Rs 2,315 Crore in Q3’FY20; up 15% YoY Q3’FY21 EBITDA at Rs 653 Crore vs. Rs 513 Crore in Q3’FY20; up 27% YoY Q3’FY21 PAT at Rs 310 Crore vs. Rs 203 Crore; up 52% YoY Q3'FY21 EPS is Rs 19.5 vs. Rs 12.8 in Q3'FY20; u
Slide 5: Update on Reorganization Proposal
Update on Reorganization Proposal Post the board approval on Oct 25, 2019 for reorganizing the businesses of the Company, in November 2019 the Company had filed with BSE Limited (BSE) and National Stock Exchange of India Limited (NSE) the Composite Scheme of Arrangement for amalgamation of certain
Slide 6: Pre-Demerger Org Structure
Pre-Demerger | Organisation & Business Structure Pre-Demerger Org Structure Jubilant Life Sciences Limited Life Science Ingredients Business (Listed on NSE & BSE) At holding Company Level Jubilant Pharma Limited Jubilant Biosys Limited Jubilant Therapeutics Limited Jubilant Life Sciences Limited (JL
Slide 7: Post-Demerger Org Structure
Post-Demerger | Organisation & Business Structure Post-Demerger Org Structure Jubilant Life Jubilant Ingrevia Limited Jubilant Pharmova Limited Sciences Limited renamed as Jubilant Pharmova Carved out Life Science 100% Limited on Feb 1, Ingredients business to be housed Jubilant Pharma Limited 2021.
Slide 8: Demerger Rationale
Demerger Rationale • Demerger will facilitate in creating a simple structure with two separate pure- Simplified Corporate Structure play entities • Greater operational efficiencies with dedicated management structure • Demerger to result in value unlocking for shareholders • Mirror shareholding spli
Slide 9: Composite Scheme of Arrangement - Key Milestones Achieved/ Upcoming
Composite Scheme of Arrangement - Key Milestones Achieved/ Upcoming 25, Oct 2019 Board approval for the Composite Scheme of Arrangement 30/31, Jan 2020 In principle approval of Stock Exchanges for the draft Composite Scheme 8, Aug 2020 NCLT convened meetings of JLL shareholders, secured & unsecured
Slide 10: Q3'FY21 Results Analysis
Ww) IBILANT Spanien Q3'FY21 Results Analysis
Slide 11: P&L Statement – Breakup Continuing and Discontinued Operations
P&L Statement – Breakup Continuing and Discontinued Operations 1 Continuing Operations PARTICULARS Q3'FY20 Q3'FY21 9M'FY20 9M'FY21 FY20 Total revenue from operations 1,518 1,771 4,407 4,519 5,976 Profit After Tax 158 219 466 401 678 EPS 9.93 13.75 29.23 25.19 42.55 Discontinued Operations2 PARTICULA
Slide 12: Q3'FY21 Financial Highlights
Q3'FY21 Financial Highlights Particulars1 Q3'FY20 Q3'FY21 YoY (%) Revenue at Rs 2,664 Crore, as compared with Rs 2,315 Crore in Revenue Q3'FY20 Pharmaceuticals 1,450 1,692 17% Life Science Ingredients 797 893 12% • Pharmaceuticals revenue at Rs 1,692 Crore as compared to Rs Contract Research and D
Slide 13: Adjusted Earnings
Adjusted Earnings Consol EBITDA S. No. Particulars Q3'FY20 Q3'FY21 YoY (%) 1 Reported EBITDA 513 653 27% 2 One-off Adjustments 3 3 3 Adjusted EBITDA 516 656 27% 4 Reported EBITDA Margin 22.2% 24.5% 5 Adjusted EBITDA Margin 22.3% 24.6% One-off Expenses S. No. Particulars Q3'FY20 Q3'FY21 1 Site Remedi
Slide 14: Pharmaceuticals Segment Highlights – Q3'FY21 (1/2)
Pharmaceuticals Segment Highlights – Q3'FY21 (1/2) Pharmaceuticals Segment Pharmaceuticals revenue was at Rs 1,692 Crore vs. Rs 1,450 Crore in 1 Q3'FY20 Particulars Q3'FY20 Q3'FY21 YoY (%) Revenue 1,450 1,692 17% Specialty Pharmaceuticals2 Specialty Pharma 764 582 (24%) • Radiopharma business cont
Slide 15: Pharmaceuticals Segment Highlights – Q3'FY21 (2/2)
Pharmaceuticals Segment Highlights – Q3'FY21 (2/2) USFDA Inspection Details Generics1 Facility Last Inspection • Revenue growth during the quarter was led by strong performance in key products in the US market and by launch of remdesivir in various countries Montreal, CMO May, 2018 including India M
Slide 16: LSI Segment Highlights – Q3'FY21
LSI Segment Highlights – Q3'FY21 1 Particulars Q3'FY20 Q3'FY21 YoY (%) LSI revenue was at Rs 893 Crore against Rs 797 Crore in Q3'FY20. Strong Revenue 797 893 12% growth witnessed in Nutritional Products and Life Science Chemicals Specialty Chemicals 293 303 3% business driven by improved pricing
Slide 17: Contract Research and Development Services – Q3'FY21
Contract Research and Development Services – Q3'FY21 Particulars1 Q3'FY20 Q3'FY21 YoY (%) Contract Research and Development Services comprises Revenue 68 79 17% Reported EBITDA 22 29 30% • Through Jubilant Biosys Limited provides innovative and Adjusted EBITDA 22 29 30% collaborative research and
Slide 18: Proprietary Novel Drugs (Jubilant Therapeutics)
Proprietary Novel Drugs (Jubilant Therapeutics) Jubilant Therapeutics is a patient-focused biopharmaceutical company working to address unmet medical needs in oncology and autoimmune diseases, with the two lead preclinical first-in-class programs transitioning to clinic over the next 12-18 months.
Slide 19: 9M’FY21 Results Analysis
9M’FY21 Results Analysis 18 18
Slide 20: 9M'FY21 Financial Highlights
9M'FY21 Financial Highlights Particulars1 9M'FY20 9M'FY21 YoY (%) Revenue Revenue at Rs 6,932 Crore vs. Rs 6,763 Crore in 9M'FY20 Pharmaceuticals 4,231 4,304 2% • Pharmaceuticals revenue at Rs 4,304 Crore vs. Rs 4,231 Crore in Life Science Ingredients 2,356 2,413 2% Contract Research and Developme
Slide 21: 9M'FY21 Adjusted Earnings
9M'FY21 Adjusted Earnings Consol EBITDA S. No. Particulars 9M'FY20 9M'FY21 YoY (%) 1 Reported EBITDA 1,438 1,457 1% 2 One-off Adjustments 60 11 3 Adjusted EBITDA 1,498 1,468 (2%) 4 Reported EBITDA Margin 21.3% 21.0% 5 Adjusted EBITDA Margin 22.2% 21.2% One-off Expenses S. No. Particulars 9M'FY20 9M'
Slide 22: Pharmaceuticals Segment Highlights – 9M'FY21
Pharmaceuticals Segment Highlights – 9M'FY21 Geography Wise Revenue Particulars 1 9M'FY20 9M'FY21 YoY (%) Particulars1 9M'FY20 9M'FY21 YoY (%) India 106 220 108% Revenue 4,231 4,304 2% North America 3,495 3,432 (2%) Specialty Pharma 2,233 1,701 (24%) Europe and Japan 341 330 (3%) CDMO 1,148 1,435 25
Slide 23: LSI Segment Highlights – 9M'FY21
LSI Segment Highlights – 9M'FY21 Particulars 1 9M'FY20 9M'FY21 YoY (%) LSI revenue at Rs 2,413 Crore vs Rs 2,356 Crore in 9M'FY20 Revenue 2,356 2,413 2% Specialty Chemicals 831 818 (2%) EBITDA at Rs 418 Crore up 34% YoY with margin of 17.3% as Nutrition and Health Solutions 373 431 15% compared
Slide 24: Contract Research and Development Services – 9M'FY21
Contract Research and Development Services – 9M'FY21 Particulars1 9M'FY20 9M'FY21 YoY (%) Revenue up 20% YoY to Rs 211 Crore led by higher demand Revenue 176 211 20% from Biotech companies for Integrated Services, DMPK, Reported EBITDA 52 67 28% Biology, and Functional Chemistry Adjusted EBITDA 52
Slide 25: Debt Profile
Debt Profile Particulars 31-Mar-20 30-Sep-20 31-Dec-20 Foreign Currency Loans (US$ m) (US$ m) (US$ m) Subsidiaries 431 435 435 Total 431 435 435 Rupee Loans (Rs Crore) (Rs Crore) (Rs Crore) Standalone 1,295 820 700 Subsidiaries 100 125 127 Total 1,395 945 827 Gross Debt (Rs Crore) (Rs Crore) (Rs Cro
Slide 26: Business outlook
Business outlook We continue to see improvement in demand in most of our business segments be it CMO, Generics, API or Life Science Ingredients Given the strong demand recovery and new business sign-ups, we believe COVID-19 is not likely to have a material impact on our overall performance durin
Slide 27: Appendix
a Pr ¥ oa (o) VA A p pend IX 26
Slide 28: Income Statement – Q3 & 9M'FY21
Income Statement – Q3 & 9M'FY21 Particulars1 Q3'FY20 Q3'FY21 YoY (%) 9M'FY20 9M'FY21 YoY (%) Total Revenue from Operations 2,315 2,664 15% 6,763 6,932 2% Pharmaceuticals 1,450 1,692 17% 4,231 4,304 2% Life Science Ingredients 797 893 12% 2,356 2,413 2% Contract Research and Development Services 68 7
Slide 29: For more information
For more information For Investors: Siddharth Rangnekar Hemant Bakhru | Pavleen Taneja CDR India Ph: +91 120 436 1002| 21 Ph: +91 22 6645 1209 E-mail: hemant.bakhru@jubl.com E-mail: siddharth@cdr-india.com pavleen.taneja@jubl.com For Media: Sudhakar Safaya Clayton Dsouza Ph: +91 120 436 1034 Madison